Search results
Wall Street Analysts Believe Napco (NSSC) Could Rally 25.14%: Here's is How to Trade
Shares of Napco (NSSC) have gained 4.7% over the past four weeks to close the last trading session at $40.22, but there could still be a solid upside left in the stock if short-term price targets of
Does Cushman & Wakefield (CWK) Have the Potential to Rally 25.71% as Wall Street Analysts Expect?
Cushman & Wakefield (CWK) closed the last trading session at $14.08, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts See a 29.75% Upside in Sony (SONY): Can the Stock Really Move This High?
Sony (SONY) closed the last trading session at $22.35, gaining 4.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
How Much Upside is Left in Cohu (COHU)? Wall Street Analysts Think 28.27%
Cohu (COHU) closed the last trading session at $52.84, gaining 3.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
Wall Street Analysts Predict a 54.26% Upside in Ameresco (AMRC): Here's What You Should Know
Ameresco (AMRC) closed the last trading session at $27.94, gaining 9.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
Pfizer Inc. PFE used its second-quarter 2026 earnings call to stress that stronger non-COVID products are offsetting a weak infection season as investment targets oncology and obesity.
Management
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
Key Points
- Interested in NewAmsterdam Pharma Company N.V.? Here are five stocks we like better.
- PREVAIL is the key near-term catalyst: NewAmsterdam expects to reach its interim event target by
Recursion Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Recursion Pharmaceuticals, Inc.? Here are five stocks we like better.
- Recursion advanced its pipeline, moving its first neuroscience target from the Roche/Genentech
Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
Shares of Si-Bone (SIBN) have gained 6.8% over the past four weeks to close the last trading session at $18.04, but there could still be a solid upside left in the stock if short-term price targets
Wall Street Analysts Believe Matson (MATX) Could Rally 27.33%: Here's is How to Trade
Matson (MATX) closed the last trading session at $205.51, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
How Much Upside is Left in SPX Technologies (SPXC)? Wall Street Analysts Think 27.76%
SPX Technologies (SPXC) closed the last trading session at $214.93, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Believe Superior Group (SGC) Could Rally 33.77%: Here's is How to Trade
Superior Group (SGC) closed the last trading session at $13.83, gaining 8.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Think American Tower (AMT) Could Surge 27.3%: Read This Before Placing a Bet
American Tower (AMT) closed the last trading session at $168.07, gaining 1.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting
Key Points
- Interested in Orion Energy Systems, Inc.? Here are five stocks we like better.
- Fiscal 2026 results improved: Revenue rose to $86.3 million from $79.7 million, gross margin increased
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München Q2 Earnings Call Highlights
Key Points
- Interested in Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München? Here are five stocks we like better.
- Munich Re remains on track for its 2026 profit target
Relmada Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Relmada Therapeutics, Inc.? Here are five stocks we like better.
- NDV-01 manufacturing is Relmada’s immediate priority as it targets an investigational new drug
Does Patterson-UTI (PTEN) Have the Potential to Rally 37.91% as Wall Street Analysts Expect?
Patterson-UTI (PTEN) closed the last trading session at $10.05, gaining 6.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts See a 34.93% Upside in Trimble (TRMB): Can the Stock Really Move This High?
Trimble Navigation (TRMB) closed the last trading session at $58.55, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
How Much Upside is Left in Gibraltar Industries (ROCK)? Wall Street Analysts Think 33.12%
Gibraltar Industries (ROCK) closed the last trading session at $50.78, gaining 20.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
Iovance Biotherapeutics (IOVA) closed the last trading session at $6.21, gaining 42.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set